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Dear Editor,
we thank Drs. Fiore and Andreana for their
comments about our paper.1 However, we
agree only in part with the majority of consid-
erations proposed by the authors as regards to
the choice to use daptomycin for the treatment
of a patient with spontaneous bacterial peri-
tonitis (SBP) due to methicillin-resistant
Staphylococcus aureus (MRSA). 
First of all, our patient showed at admission
a severe thrombocytopenia (platelet count of
39×109/L) and the use of linezolid (LZD) can-
not be encouraged in these cases. As matter of
fact, a recent study revealed significant inter-
group differences in duration of LZD treatment
prior to thrombocytopenia and it has been
reported also within 8 days of therapy.2
Furthermore, among patients with acute or
chronic liver failure a low baseline platelet
count has been identified as an independent
risk factor for development of severe thrombo-
cytopenia during LZD therapy.3 The available
data and the clinical judgment do not suggest
to recommend LZD as first choice in patients
with chronic liver failure or cirrhosis and low
baseline platelet count.
Moreover, we disagree with comments
about the comparison of daptomycin and LZD
therapy for the treatment of vancomycin-resis-
tant enterococci infection. Compared to LZD, it
is well known that daptomycin has a reduced
activity against enterococci and it is not con-
sidered a first-line option in patients with
enterococcal infection. But we think that this
observation is not appropriate for our case
since we were treating a SBP due to MRSA. It
is not necessary to review in this paper the
body of evidence supporting the use of dapto-
mycin in patients with MRSA infection.4
Furthermore, we presented a summary of data
(Table 2 of our publication)1 suggesting a role
for daptomycin in primary or secondary bacte-
rial peritonitis. These observations seem to be
confirmed by the randomized clinical trial of
Piano and coworkers, who demonstrated a
high efficacy of daptomycin combined to
meropenem for the treatment of nosocomial
SBP.5
Finally, since we have contributed with clin-
ical and pharmacological studies to the assess-
ment of the better daptomycin dosage in criti-
cally ill patients,6-8 we strongly agree that a
high dose of daptomycin should be considered
in these situations. However, we have to out-
line that our patient had an acute kidney fail-
ure and daptomycin dosage should be adapted
in these cases (recommendation is to use dap-
tomycin every 48 hours if creatinine clearance
is less than 35 mL/m). Thus the dosage we
decided to administer was significantly high in
the former cases.
In conclusion, there is growing evidence of
an effective role of daptomycin in SBP
episodes in cirrhotic patients. Considering the
importance to ensure a broad-spectrum antibi-
otic therapy in cirrhotic patients with health-
care-associated infections,9,10 daptomycin may
be considered a potential option in these
cases.
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